BACKGROUND: Administration of abciximab during primary percutaneous coronary intervention (PCI) reduces major adverse cardiac events (MACE) in patients with ST-elevation myocardial infarction (STEMI). Intracoronary (IC) abciximab bolus application during PCI results in high local drug concentration, improved perfusion, reduction of infarct size, and less microvascular obstruction early after infarction. Aim of this study was to investigate whether the early benefits of an IC abciximab administration in STEMI patients undergoing PCI are sustained at 6 months. METHODS: We performed 6-month follow-up of 154 STEMI patients undergoing PCI, who were randomised to either IC (n = 77) or intravenous (IV) (n = 77) bolus abciximab administration with subsequent 12-h intravenous infusion. The primary endpoint was infarct size at 6-month follow-up as assessed by delayed enhancement magnetic resonance imaging. Clinical end points were MACEs within 6 months after infarction. RESULTS: The median infarct size after 6 months was significantly reduced in the IC abciximab group (16.7 vs. 24.1%, p = 0.002). A significant recovery of LV function was only observed in the IC abciximab group (p < 0.001), and IC abciximab group patients had significantly less adverse remodelling as compared to standard IV abciximab treatment (p = 0.03). These beneficial effects also translated into a strong trend towards a reduced MACE rate in the IC abciximab group at 6-month follow-up (10 vs. 21%, p = 0.07). CONCLUSIONS:Intracoronary abciximab application in STEMI patients undergoing PCI is superior to standard IV treatment with respect to infarct size, recovery of LV function and reverse remodelling 6 months after infarction.
RCT Entities:
BACKGROUND: Administration of abciximab during primary percutaneous coronary intervention (PCI) reduces major adverse cardiac events (MACE) in patients with ST-elevation myocardial infarction (STEMI). Intracoronary (IC) abciximab bolus application during PCI results in high local drug concentration, improved perfusion, reduction of infarct size, and less microvascular obstruction early after infarction. Aim of this study was to investigate whether the early benefits of an IC abciximab administration in STEMI patients undergoing PCI are sustained at 6 months. METHODS: We performed 6-month follow-up of 154 STEMI patients undergoing PCI, who were randomised to either IC (n = 77) or intravenous (IV) (n = 77) bolus abciximab administration with subsequent 12-h intravenous infusion. The primary endpoint was infarct size at 6-month follow-up as assessed by delayed enhancement magnetic resonance imaging. Clinical end points were MACEs within 6 months after infarction. RESULTS: The median infarct size after 6 months was significantly reduced in the IC abciximab group (16.7 vs. 24.1%, p = 0.002). A significant recovery of LV function was only observed in the IC abciximab group (p < 0.001), and IC abciximab group patients had significantly less adverse remodelling as compared to standard IV abciximab treatment (p = 0.03). These beneficial effects also translated into a strong trend towards a reduced MACE rate in the IC abciximab group at 6-month follow-up (10 vs. 21%, p = 0.07). CONCLUSIONS: Intracoronary abciximab application in STEMI patients undergoing PCI is superior to standard IV treatment with respect to infarct size, recovery of LV function and reverse remodelling 6 months after infarction.
Authors: Stefanie Schulz; K Anette Birkmeier; Gjin Ndrepepa; Werner Moshage; Franz Dotzer; Kurt Huber; Josef Dirschinger; Melchior Seyfarth; Albert Schömig; Adnan Kastrati; Julinda Mehilli Journal: Clin Res Cardiol Date: 2010-06-27 Impact factor: 5.460
Authors: Enrico Romagnoli; Francesco Burzotta; Carlo Trani; Mario A Mazzari; Giuseppe G L Biondi-Zoccai; Maria De Vita; Floriana Giannico; Giampaolo Niccoli; Francesco Prati; Antonio G Rebuzzi; Rocco Mongiardo; Filippo Crea Journal: Int J Cardiol Date: 2005-12-07 Impact factor: 4.164
Authors: F J Neumann; A Kastrati; C Schmitt; R Blasini; M Hadamitzky; J Mehilli; M Gawaz; M Schleef; M Seyfarth; J Dirschinger; A Schömig Journal: J Am Coll Cardiol Date: 2000-03-15 Impact factor: 24.094
Authors: S J Brener; L A Barr; J E Burchenal; S Katz; B S George; A A Jones; E D Cohen; P C Gainey; H J White; H B Cheek; J W Moses; D J Moliterno; M B Effron; E J Topol Journal: Circulation Date: 1998-08-25 Impact factor: 29.690
Authors: Gjin Ndrepepa; Julinda Mehilli; Markus Schwaiger; Helmut Schühlen; Stephan Nekolla; Stefan Martinoff; Claus Schmitt; Josef Dirschinger; Albert Schömig; Adnan Kastrati Journal: J Nucl Med Date: 2004-05 Impact factor: 10.057
Authors: Raisuke Iijima; Gjin Ndrepepa; Julinda Mehilli; Franz-Josef Neumann; Stefanie Schulz; Jurriën ten Berg; Olga Bruskina; Franz Dotzer; Josef Dirschinger; Peter B Berger; Albert Schömig; Adnan Kastrati Journal: Clin Res Cardiol Date: 2007-11-28 Impact factor: 5.460
Authors: H E Speich; A D Earhart; S N Hill; S Cholera; T J Kueter; J N Smith; M M White; L K Jennings Journal: J Thromb Haemost Date: 2009-06 Impact factor: 5.824
Authors: Andreas Rolf; Birgit Assmus; Volker Schächinger; Johannes Rixe; Susanne Möllmann; Helge Möllmann; Stefanie Dimmeler; Andreas M Zeiher; Christian W Hamm; Thorsten Dill Journal: Clin Res Cardiol Date: 2011-06-17 Impact factor: 5.460
Authors: Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf Journal: Clin Res Cardiol Date: 2012-05-06 Impact factor: 5.460
Authors: Jens Wiebe; Helge Möllmann; Astrid Most; Oliver Dörr; Kay Weipert; Johannes Rixe; Christoph Liebetrau; Albrecht Elsässer; Stephan Achenbach; Christian Hamm; Holger Nef Journal: Clin Res Cardiol Date: 2013-10-18 Impact factor: 5.460
Authors: Damien Legallois; Amir Hodzic; Joachim Alexandre; Charles Dolladille; Eric Saloux; Alain Manrique; Vincent Roule; Fabien Labombarda; Paul Milliez; Farzin Beygui Journal: Heart Fail Rev Date: 2022-01 Impact factor: 4.214